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No evidence for the presence of genetic variants predisposing
to psychotic disorders on the non-deleted 22q11.2 allele of
VCFS patients
M Guipponi1,9, F Santoni1,9, M Schneider2, C Gehrig1, XB Bustillo1, WR Kates3, B Morrow4, M Armando2,5, S Vicari5, F Sloan-Béna1,
M Gagnebin1, V Shashi6, SR Hooper7, S Eliez2 and SE Antonarakis1,8
The velo-cardio-facial syndrome (VCFS) is caused by hemizygous deletions on chromosome 22q11.2. The VCFS phenotype is
complex and characterized by frequent occurrence of neuropsychiatric symptoms with up to 25–30% of cases suffering from
psychotic disorders compared with only ~ 1% in the general population (odds ratio≈20–25). This makes the 22q11.2 deletion one of
the most prominent risk factors for schizophrenia. However, its penetrance for neuropsychiatric phenotypes is incomplete
suggesting that additional risk factors are required for disease development. These additional risk factors could lie anywhere on the
genome, but by reducing the normal diploid to a haploid state, the 22q11.2 deletion could result in the unmasking of otherwise
recessive alleles or functional variants on the non-deleted 22q11.2 allele. To test this hypothesis, we captured and sequenced the
whole 22q11.2 non-deleted region in 88 VCFS patients with (n= 40) and without (n= 48) psychotic disorders to identify genetic
variation that could increase the risk for schizophrenia. Single nucleotide variants (SNVs), small insertions/deletions (indels) and
copy number variants were called and their distributions were compared between the two diagnostic groups using variant-,
gene- and region-based association tests. None of these tests resulted in statistical evidence for the existence of a genetic variation
in the non-deleted allele that would increase schizophrenia risk in VCFS patients. Power analysis showed that our study was able to
achieve 480% statistical power to detect association of a risk variant with an odd ratio of ⩾ 22. However, it is certainly under-
powered to detect risk variant of smaller effect sizes. Our study did not provide evidence that genetic variants of very large effect
size located on the non-deleted 22q1.2 allele in VCFS patients increase the risk for developing psychotic disorders. Variants with
smaller effects may be located in the remaining 22q11.2 allele and elsewhere in the genome. Therefore, whole exome or even
genome sequencing for larger sample size would appear to be the next logical steps in the search for the genetic modifiers of the
22q11.2-deletion neuropsychiatric phenotype.
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INTRODUCTION
The velo-cardio-facial syndrome (VCFS), also known as the
22q11.2-deletion syndrome (22q11.2DS), is the most common
microdeletion syndrome affecting ~ 1 in 2000–4000 individuals.1 It
is caused by hemizygous deletions on chromosome 22q11.2,
which occur predominantly de novo (~90% of cases).2 The majority
of individuals have a 3 Mb deletion, whereas others (~10%) have a
nested 1.5 Mb deletion. The occurrences of 22q11.2 deletions are
associated with non-allelic homologous recombination between
specific segmental duplications.3
The VCFS phenotype is extremely diverse manifesting with
variable expression and incomplete penetrance in multiple
organs/systems such as velopharyngeal insufficiency with cleft
palate, speech disorders, cardiac defects, microcephaly, short
stature, typical facial appearance, auricular anomalies, cognitive
problems and neuropsychiatric manifestations.1 Of interest, VCFS
patients show a greatly increased risk of developing psychotic
disorders, including schizophrenia (SCZ).4 In late adolescence and
early adulthood, up to 30% of all individuals with VCFS develop
psychotic disorders.5
SCZ is a severe mental disorder that causes abnormal cognition
and perceptions and affect ~ 1% of the population worldwide.6
Although the exact etiology is largely unknown, its genetic
component is likely to consist of a combination of common and
rare risk variants of small or large effect size, respectively. The
22q11.2 deletion is known as one of the strongest genetic risk
factors for SCZ.7 However, the exact mechanism by which this
deletion increases the risk to develop psychotic disorders in some,
but not all VCFS individuals is currently unknown.
Several variables, such as parental origin and size of the
deletion as well as additional genomic variants could influence the
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neuropsychiatric outcome of the 22q11.2 deletion. Regarding the
contribution of parental origin of the deletion, the results are
mixed. Basset et al.8 found no evidence for an effect of parental
origin of the 22q11.2 deletion on SCZ risk.8 However, Green et al.9
showed that maternal origin of the deletion was associated with
an increased prevalence of psychotic disorders when compared
with paternal origin.9
When considering the size of the 22q11.2 deletion, there
appeared to be no relationship between the development of SCZ
and the size of the deletion.1 Consistently, Green et al.9 showed
that deletion size did not have an effect on the distribution of
psychotic disorders between individuals with typical (3 Mb) versus
atypical deletions.9
Finally, the presence of additional copy number variants (CNV)
as potential genetic modifiers of the 22q11.2 neuropsychiatric
phenotype has been studied in a sample of 100 VCFS patients (44
with SCZ).8 No enrichment of novel inherited CNV or evidence of
de novo CNVs outside the 22q11.2 region was found indicating
that hemizygosity of the 22q11.2 locus appears to be the major
CNV-related risk factor for SCZ in VCFS individuals. In a similar
study, Williams et al.10 performed genome-wide CNV analysis in a
cohort of 48 VCFS cases (23 with psychosis) and showed that VCFS
subjects with psychosis had a significant increase in the average
size of CNV as well as an enrichment for CNV overlapping loci
previously implicated in neuropsychiatric disorders.10
Another hypothesis, that has not yet been systematically
investigated, lies in the fact that allelic variation, such as single
nucleotide variants (SNVs), indels and CNVs, within the non-
deleted 22q11.2 allele could influence the neuropsychiatric
outcome of the 22q11.2 deletion. According to this hypothesis,
individuals carrying recessive variants in genes and/or functional
elements predisposing to psychotic disorders would become
hemizygote for these variants in the presence of the 22q11.2
deletion.11,12
To investigate the presence of genetic variants including SNVs,
indels and CNVs that may contribute to the development of
psychotic disorder in patients with VCFS, we have captured and
sequenced the whole 22q11.2 non-deleted allele in 88 VCFS
individuals, 40 who suffer from psychotic disorders and 48 who do
not. Our study did not identify any genetic variants that would
influence the variable penetrance of psychotic disorders asso-
ciated with the 22q11.2 deletion suggesting that such variants
may be located elsewhere in the genome.
MATERIALS AND METHODS
VCFS patient recruitment
VCFS individuals carrying the 3 Mb 22q11.2 deletion were recruited and
psychiatrically assessed. This research project was approved by the ethics
committee of all participating centers. All participants or legally authorized
representatives provided their written informed consent.
Participants from the Geneva cohort were recruited in Switzerland,
France, Belgium, and Great Britain through advertisements in patient
associations or word of mouth. Participants from the Rome cohort were
referred from the Genetic Clinical Unit of the Bambino Gesù Hospital and
through advertisement in patient associations. Written informed consent
from the participants and their parents was collected under protocols
approved by local Institutional Ethical Review Boards. The Duke
participants were recruited from the medical genetics clinics at Duke
and neighboring medical centers in North Carolina as well as from the
North Carolina 22q11 support group. All procedures and sample collection
were performed after informed consent, under a protocol approved by the
Duke Institutional Review Board. The SUNY participants were recruited
from the International Center for the Evaluation, Treatment and Study of
Velo-Cardio-Facial Syndrome at SUNY Upstate Medical School, as well as
from 22q11DS support groups. Written informed consent from participants
and their parents was collected according to approved protocols by the
SUNY Upstate Institutional Review Board.
22q11.2 allele sequencing and variant calling
Genomic DNA extracted from blood was used. The entire repeat-masked
sequence of the 3 Mb 22q11.2 deletion and flanking sequences (hg19
genomic coordinates: chr22: 18 400 394–22 600 038) was captured using a
SureSelect custom design kit (Agilent Technologies, Santa Clara, CA, USA)
(Supplementary bed file contains the chromosomal position of the
captured regions after merging probes with overlapping coordinates).
High-throughput sequencing was performed on a HiSeq2000 (Illumina, San
Diego, CA, USA) using manufacturer’s recommendations. Demultiplexed
fastq files were obtained using the Illumina CASAVA v1.8.2 software and
processed by our ‘in-house’ pipeline running on the Vital-IT (http://www.
vital-it.ch) Center for high-performance computing of the Swiss Institute of
Bioinformatics (SIB). Specifically, Burrows–Wheeler Aligner (BWA) was used
to align the sequencing reads to the human reference genome NCBI build
(GRCh37/hg19). SAMtools was used to remove duplicate reads. SNVs and
indels were called using bcftools and Pindel 0.2.4, respectively. The
minimum number of independent reads required for variant calling was
set at 4. SNV and indels were then collected in a unique VCF file and
annotated using the ANNOVAR package.13
ERDS software was used to infer CNVs (http://www.utahresearch.org/
mingfuzhu/erds/).14
Association tests
All association tests performed were based on Fisher’s exact test with
Bonferroni correction for multiple testing set at ⩽ 5%.
RESULTS
VCFS patients
VCFS individuals carrying the 3 Mb 22q11.2 deletion were
included in the present study. Participants were separated in
two extreme subgroups according to their clinical phenotype:
control (N= 48) versus cases (N= 40). Minimal age of inclusion for
the control group was set at 15 years to limit the presence of false
negatives (that is, participants who will develop a psychotic
disorder later in life). The participants’ psychiatric status was
assessed during a structured clinical interview with various clinical
instruments, depending on the age and recruitment site: the
Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders (SCID-
I) and/or the Diagnostic Interview for Children and Adolescent
(DICA), along with the psychotic disorders supplement of the
K-SADS-PL. Control participants were rated as having no or
minimal lifetime history of any psychotic symptoms (hallucina-
tions or delusions). On the other hand, cases met criteria for
a DSM-IV psychotic disorder at the last available assessment.
Clinical and epidemiological data are summarized in Supple-
mentary Table 1.
22q11.2 chromosomal region-sequencing data
After the removal of duplicate reads, 20 (±8 s.d.) million mapped
to the targeted chromosomal region. These reads represented an
average coverage of at least 20 × for 98.2% (±1.75 s.d.) and 98.2%
(±1.91 s.d.) of the hemizygote target region for VCFS_cases and
VCFS_controls, respectively. On average, 4674 (min: 3578; max:
6568) and 4585 (min: 3375; max: 6381) high-quality variants
(Samtools QS ⩾ 50 and Pindel QS ⩾ 600) were detected per
individual in VCFS_cases and VCFS_controls, respectively.
Supplementary Tables 2 and 3 summarize sequencing coverage
and variant calling results.
Power analysis
The prevalence of psychotic disorder in the general population
and in VCFS patients has been estimated as 1% and 30%,
respectively,4 which corresponds to an odd ratio (OR) of ~ 30. Our
sample size (40 cases and 48 controls) gives 80% statistical power
to detect an OR422 for a genetic variant with risk allele frequency
of 0.01 at the 0.05 level of significance (simulation performed with
power.fisher.test as implemented in the R software) Figure 1.
Genetics of psychosis in VCFS patients
M Guipponi et al
2
Translational Psychiatry (2017), 1 – 5
Association analysis
Association tests for SNVs and indels. Given the prevalence of
psychotic disorders in VCFS, only high-quality hemizygous variants
with SAMtools and PINDEL quality scores of ⩾ 50 and ⩾ 600,
respectively, and with a minimal allele frequency of ⩽ 30% in
public databases (http://www.ncbi.nlm.nih.gov/SNP/ and http://
exac.broadinstitute.org/) were retained for analysis. Moreover,
variants present only once in our dataset (88 samples) were
excluded. Only variants respecting the above-mentioned filters
(a total of 4176) were considered in further analysis.
Three different association tests based on Fisher’s exact test
were employed. (i) Variant-based association test that compares
the frequency of each variant between cases and controls
(significance threshold corrected for the number of variants:
Po10− 5), (ii) Gene-based association test that compares the
burden of coding and splice-site variants (±6 nt from the donor-
acceptor site) for each gene between cases and controls
(significance threshold corrected for the number of genes
(n= 73) in the region 22q11.2: Po10− 3) and (iii) Region-based
association study that compares the burden of variant located
within a sliding window of 1, 5 and 10 kb between cases and
controls (significance threshold corrected for the number of
windows ( = number of variants): Po10− 5). None of the three
association studies performed (variant-, gene- and region-based)
yielded a signal above the false discovery rate-corrected threshold
of significance (Figure 2).
Association test for CNV data. Two different approaches were
used to test for association of potential CNVs and psychotic
disorders in VCFS patients. We first calculated for each sample the
normalized coverage per nucleotide (number of reads overlapping
the nucleotide/total number of reads) and applied the Fisher test
to identify a statistically significant difference between VCFS_cases
and VCFS_controls independently for each nucleotide. We then
used ERDS to infer CNV in each sample. The coverage-based test
did not identify any significant difference between cases and
control. This result was confirmed by the analysis using ERDS in
which neither deletions nor duplications were detected.
DISCUSSION
In this study, we sought to test the hypothesis that specific genetic
variants, including SNVs, indels and CNVs, located on the
hemizygous 22q11.2 region might modify the risk of VCFS
individuals to develop psychotic disorder. We sequenced the
entire hemizygous 22q11.2 allele in 88 subjects with the 22q11.2
deletion, 40 who suffer from psychotic disorders and 48 who do
not. The distribution of genomic variants, including SNVs, indels
Figure 1. Power analysis. This study had 80% power to detect an
odd ratio (OR) of 22.
3
5
5
Figure 2. Log10 P-value plotted against chromosome 22q11.2 genomic coordinates (http://genome.ucsc.edu/) for the variant-, gene- region-
based association test. Horizontal dotted lines show level of statistical significance corrected for the number of variants, genes and windows;
Po10− 5, Po10− 3 and Po10− 5, respectively.
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and CNVs, were compared between the two diagnostic
groups using several association tests. We did not observe any
difference in the distribution of genetic variants in any of the
association tests performed (variant-, gene-, region-based tests)
between the two diagnostic groups. These results did not support
the existence of specific genetic variants for the development of
psychotic disorder in the non-deleted 22q11.2 allele in VCFS
patients.
A limitation of our study resides in the fact that some of the
VCFS_controls may not have yet entered the age when psychotic
symptoms become more prevalent. The average age of onset for
psychotic disorders in VCFS individuals varies between early
adolescence and early adulthood with a mean in the late teens
and early 20s.15 The mean age of the VCFS_controls at their last
evaluation is 22.17 ± 6.07 years and thus we cannot exclude that
some might develop psychotic symptoms later in life, which may
have deflated our power to detect a positive association signal.
We repeated this analysis by removing control individuals aged
o20 years. The results were very similar to what obtained
considering all individuals with no signal above the false discovery
rate-corrected threshold of significance (data not shown). The two
age distributions (mean± s.d.) were very similar: 22.8 ± 6 years for
the VCFS_cases versus 22.2 ±− 6 years for the VCFS_controls.
On the basis of our statistical power calculation, our study
appeared well-powered to detect association of the expected effect
size. Indeed, the prevalence of psychotic disorder in the general
population and in VCFS patients has been estimated as 1% and
30%, respectively.4 The odds of psychotic disorder are 30× higher
in VCFS patients than in the general population which corresponds
to an OR of 30. Our sample size (40 cases and 48 controls) gives
80% power to detect one variant with an OR422 at the 0.05 level
of significance (Figure 2). However, our study design appeared
definitely under-powered if the genetic architecture of the trait is
made of many risk variants, each of small effect size.
Although not significant, the best association signals point
to the ARVCF gene (chr22:19 '957 '402–20 '004 '309 (hg19);
NM_001670, which is a member of the catenin family. This family
of genes has an important role in the formation of adherens
junction complexes, which are thought to facilitate communica-
tion between the inside and outside environments of a cell.16
Hence, ARVCF may have a role in intracellular signaling during
embryonic development and be an integral part of the
neurodevelopmental hypothesis for SCZ.17 Several studies have
investigated the role of ARVCF in SCZ susceptibility. Sanders
et al.18 suggest a possible role for ARVCF as a candidate gene
for SCZ via alterations in neural development.18 Mas et al.19,20
provided further evidence for an association of ARVCF with
SCZ.19,20 Interestingly, this gene has been recently shown to
influence neurocognitive and neuroanatomical intermediate
phenotypes in patients with SCZ.21 However, others studies did
not find positive association between ARVCF and SCZ.22–24
Whether this finding represent genuine association signal or is
simply an effect of an under-powered study arising from a modest
sample sizes remains to be determined. Larger, sufficiently powered
studies in independent cohorts would be needed to ascertain what
role, if any, genetic variants in the hemizygous 22q11.2 allele have
in the risk of VCFS patients for developing psychotic disorders.
Another line of research would be the study of epigenetic
processes such as DNA methylation and histone modifications in
brain tissues. Indeed aberrant epigenetic regulation and the
resulting transcriptional dysregulation may contribute to the
development of psychotic disorders in VCFS individuals. However,
the investigation of these effects is beyond the scope of our study
and presents non-trivial technical and ethical challenges related to
the analysis of epigenetic signatures in brain tissues.
Our study suggests that the putative causative variant(s) of very
large effect for SCZ risk in VCFS are located outside of the 22q11.2
hemizygote region. Variants with smaller effects may be located in
the remaining 22q11.2 allele and elsewhere in the genome. Another
possibility is that there may be neurocognitive and neuroanatomical
intermediate phenotypes through which genetic variants with the
non-deleted 22q11.2 region are directly or indirectly influencing risk
for SCZ. In any case, exome or genome sequencing of large cohort
of cases and controls may be considered.
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